Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- (-) Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 108 Results
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…
Could expanding pre-deductible coverage help those with chronic conditions?
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
Peer-reviewed Journal Editors' Views on Real-world Evidence
A study published in the International Journal of Technology Assessment in Health Care reveals that real-world evidence is considered valuable by the editors of peer-reviewed journals—if it meets…
Journal Editors Value Real-World Evidence—With Conditions
New research from the Department of Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy and the National Pharmaceutical Council reveals that real-world evidence …
A Precision Paradigm for Value Assessment: How Frameworks Can Account for Personalized Medicine to Inform Payers, Providers, Innovators and Patients
Personalized Medicine Coalition Senior Vice President of Science Policy Daryl Pritchard, PhD, explores personalized medicine and value assessment frameworks.
Considerations When Using ICER's Value Assessments
This week we read with great interest an article posted on the Health Affairs Blog that directly responded to National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois’ Sept. 17…
When and How is Real-World Evidence Useful in Payer Decision-Making?
Research published in Value in Health from the National Pharmaceutical Council and the University of Arizona School of Pharmacy sheds more light on how real-world evidence is used in decision-making…
Real-World Evidence: Useful in the Real World of United States Payer Decision-Making? How? When? And What Studies?
Research published in Value in Health on real-world evidence provides a deeper understanding of when and how managed care organizations use RWE in decision-making, and how to increase its use.
Why the VA Should Proceed with Caution on ICER Collaboration
In a new blog published by Health Affairs, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, expands on our initial thoughts on the collaboration between the Institute…
Understanding Real-World Evidence
NPC explores the benefits and challenges with the use of real-world evidence in this first article in a series on this topic.
Information Wanted: Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers
Payers and providers were surveyed to understand the type of health care economic information (HCEI) they desire and value in the current and future health care environment, as well as the potential…
Making Real-World Evidence “Real” for Patients
As real-world evidence (RWE) becomes more broadly used in health care, it’s important to ensure that patients understand what RWE is, determine and address the questions and concerns patients…
Value Depends on Real-World Evidence
In his latest commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard examines the challenges with developing, analyzing, using and communicating real-world evidence in…
Will Value Assessment Frameworks Promote Health Value and Access for Veterans?
NPC expressed concerns about the partnership between the Institute for Clinical and Economic Review and the U.S. Department of Veterans Affairs Pharmacy Benefits Management Services office to…
NPC Evaluates ICER’s Revised Value Assessment Framework
The Institute for Clinical and Economic Review (ICER) today released its revised value assessment framework, which included a number of changes reflected in NPC's extensive public comments, but NPC…
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study
Researchers conducted cross-framework comparisons of multiple myeloma assessments using four value assessment frameworks and examined the consistency of findings across three case studies.
Why Value Framework Assessments Arrive at Different Conclusions
New peer-reviewed research from the National Pharmaceutical Council (NPC) found inconsistencies in how four value frameworks assessed multiple myeloma treatments.